Voyager Therapeutics Sets Annual Meeting for June 27
Ticker: VYGR · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1640266
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting, director-election
TL;DR
Voyager's annual shareholder meeting is June 27th - vote for directors!
AI Summary
Voyager Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting that its annual meeting of stockholders will be held on June 27, 2024. At this meeting, stockholders will vote on the election of two Class II directors, Mr. Steven M. R. Smith and Dr. Sarah L. Hough, for a three-year term. The company is headquartered in Lexington, Massachusetts.
Why It Matters
This filing informs shareholders about the upcoming annual meeting where key decisions regarding board composition will be made, impacting the company's governance and strategic direction.
Risk Assessment
Risk Level: low — This is a routine corporate filing announcing a shareholder meeting and director nominations, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- June 27, 2024 (date) — Annual Meeting Date
- Mr. Steven M. R. Smith (person) — Director Nominee
- Dr. Sarah L. Hough (person) — Director Nominee
- Lexington, Massachusetts (location) — Company Headquarters
FAQ
When is Voyager Therapeutics' annual meeting of stockholders?
The annual meeting of stockholders is scheduled for June 27, 2024.
Who are the director nominees for the upcoming annual meeting?
The director nominees are Mr. Steven M. R. Smith and Dr. Sarah L. Hough.
What is the term for the elected directors?
The elected directors will serve a three-year term.
What is the company's principal executive office location?
The company's principal executive offices are located at 75 Hayden Avenue, Lexington, Massachusetts.
What is the filing date of this 8-K report?
This 8-K report was filed on June 6, 2024.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-06-06 16:04:29
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select M
Filing Documents
- tm2416570d1_8k.htm (8-K) — 36KB
- 0001104659-24-069063.txt ( ) — 204KB
- vygr-20240605.xsd (EX-101.SCH) — 3KB
- vygr-20240605_lab.xml (EX-101.LAB) — 33KB
- vygr-20240605_pre.xml (EX-101.PRE) — 22KB
- tm2416570d1_8k_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. Voyager Therapeutics, Inc. ("Voyager") held its Annual Meeting of Stockholders on June 5, 2024. The following is a summary of the matters voted on at that meeting. (a) Voyager's stockholders elected Michael Higgins, Jude Onyia, Ph.D., and Nancy Vitale, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, subject to his or her earlier death, resignation, or removal. The results of the stockholders' vote with respect to the election of such Class III directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Michael Higgins 30,865,370 6,932,691 8,600,728 Jude Onyia, Ph.D. 34,864,862 2,933,199 8,600,728 Nancy Vitale 31,262,994 6,535,067 8,600,728 (b) Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers. The results of the stockholders' vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 35,949,375 1,711,367 137,319 8,600,728 (c) Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders' vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 46,278,029 72,375 48,385 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 6 , 2024 VOYAGER THERAPEUTICS, INC. By: /s/ Alfred Sandrock, M.D., Ph.D. Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director (Principal Executive Officer) 3